Know the Latest MASH Treatment Options

June 2026

The latest indication for injectable semaglutide (Wegovy) will increase focus on metabolic dysfunction-associated steatohepatitis (MASH).

About 15 million adults in the US have MASH...and it’s on the rise.

We know MASH can progress to fibrosis, cirrhosis, or liver failure.

Get concise advice on drug therapy, plus unlimited access to CE

Hospital Pharmacist's Letter membership benefits include:

12 issues every year — what you need to know and do, right now
Quick, practical reference charts and tools
Comprehensive CE library to meet license renewal and state requirements
Multiple course formats including live webinars, podcasts, and CE-in-the-Letter to match your learning style
Plus much more!

Choose the right tier for your needs today.

Already a subscriber? Log in

Volume pricing available. Get a quote